ERBB2 and neoplasm: In fact, our preliminary in vivo data showed no additional benefit of PD-1 blockade to the HER2-BsAb therapeutic efficacy (data not shown), even though tumor PD-L1 expression was upregulated substantially following T cell infiltration (Fig. 4E).